This discussion between Charles Christy, Director of Commercial Solutions for Ibex Dedicate and Anthony Davis from Dark Horse Consulting Group looks at how a new level of visibility for the biopharma manufacturing sector has changed relationships, investments, and capabilities. The conversation explores not only the rapid adjustments made in response to the urgent concerns regarding vaccine production but also the transformations made to accommodate new modalities and considerations around global manufacturing capacity.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center